On a recent sunny afternoon, the management team of the J. David Gladstone Institutes took a little walk through a construction site, on a path winding along Mission Creek greenspace and across the Fourth Street bridge.
Research published in the journal "Neuron" highlights the work of San Francisco scientists.In the near future, medicine already available for other conditions could be used for Alzheimer's.
Researchers at the Gladstone Institute of Neurological Disease ( GIND ) and Baylor College of Medicine have discovered a mechanism by which the protein Amyloid-ß (Aß) may impair neurological functions in Alzheimer's disease. Aß, which is known to accumulate in the brains of Alzheimer patients, has long been a focus of research into the causes and treatment of the disease. In a study published in the journal Neuron , Gladstone scientists found that Aß triggers abnormal overexcitation of the very brain networks that are responsible for learning and memory.
Lowering the level of one protein involved in Alzheimer's disease appears to prevent some of its disabling symptoms, according to a report published in the journal Science.
By cutting levels of a brain protein called "tau," scientists were able to preserve the memory and lifespans of mice genetically engineered to develop Alzheimer's disease.
Scientists at the Gladstone Institute of Neurological Disease ( GIND ) have discovered that reducing levels of the protein tau can prevent seizures and neurological deficits related to Alzheimer's disease.
Dr. Fen-Biao Gao at the Gladstone Institute of Neurological Disease was awarded $791,000 to study a new regulatory pathway that may contribute to mental disorders and age-dependent neurological diseases including autism.
